What was Pfizer's revenue performance in the third quarter of 2011?

Pfizer's revenue for the third quarter of 2011 was $17.2 billion, an increase of 7% compared to $16.0 billion in the same period of 2010. This growth was primarily driven by key biopharmaceutical products, favorable foreign exchange, and the inclusion of King Pharmaceuticals' revenues.

How did Pfizer's net income change compared to the previous year?

Pfizer reported a net income attributable to Pfizer Inc. of $3.74 billion for the third quarter of 2011, a significant increase from $0.11 billion in the third quarter of 2010. This improvement was largely due to higher income from continuing operations, a decrease in the effective tax rate, and the absence of substantial impairment charges that impacted the prior year's results.

What are the key strategic initiatives Pfizer is pursuing?

Pfizer is actively pursuing several strategic initiatives, including the integration of its acquisition of King Pharmaceuticals, ongoing cost-reduction and productivity initiatives, and the exploration of strategic alternatives for its Animal Health and Nutrition businesses. The company also continues to invest in research and development to fuel its pipeline of new products.

What is the outlook for Pfizer's major products like Lipitor?

While key products like Lyrica and the Prevnar franchise showed strong growth, Lipitor's performance was mixed. U.S. revenues for Lipitor increased by 13% in Q3 2011 due to price increases and continued promotion, but international revenues declined due to loss of exclusivity in several markets. Pfizer anticipates further impacts from the upcoming loss of exclusivity for Lipitor in the U.S. at the end of November 2011.

PFE 10-Q Filed Nov 10, 2011

Summary

Pfizer Inc. reported strong revenue growth of 7% for the third quarter of 2011, reaching $17.2 billion, primarily driven by key biopharmaceutical products like Lipitor and Lyrica, as well as favorable foreign exchange rates and the inclusion of King Pharmaceuticals. This growth was partially offset by the loss of exclusivity for several products and the impact of U.S. healthcare reform. Net income for the quarter saw a significant increase, benefiting from the absence of large impairment charges recorded in the prior year and a lower effective tax rate. The company also continues to manage its operations through various initiatives, including cost reductions and productivity improvements. Pfizer is actively exploring strategic alternatives for its Animal Health and Nutrition businesses, aiming to enhance shareholder value and sharpen its focus on core biopharmaceutical operations. The company reiterated its full-year 2011 financial guidance and provided 2012 targets, signaling confidence in its strategic direction despite ongoing industry and economic challenges.

Key Highlights

1Revenues increased 7% to $17.2 billion in Q3 2011, driven by strong performance in key biopharmaceutical products and favorable foreign exchange.
2Net income attributable to Pfizer Inc. was $3.74 billion, a substantial increase from $0.11 billion in Q3 2010, due to lower expenses and a lower effective tax rate.
3The company acquired King Pharmaceuticals for approximately $3.6 billion in early 2011, with its results included from January 31, 2011.
4Pfizer announced plans to explore strategic alternatives for its Animal Health and Nutrition businesses.
5The company reiterated its full-year 2011 revenue guidance of $66.2 billion to $67.2 billion and reported diluted EPS of $0.48 for the quarter.
6Lipitor revenue in the U.S. increased 13% year-over-year in Q3 2011, while international revenues saw a decline due to loss of exclusivity.
7Restructuring charges and acquisition-related costs totaled $1.1 billion in Q3 2011, impacting earnings but reflecting ongoing integration and efficiency initiatives.

PFIZER INC Quarterly Report for Q3 Ended Oct 2, 2011

Summary

Key Highlights

Frequently Asked Questions